115 related articles for article (PubMed ID: 7741141)
1. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism.
Bridey F; Dreyfus M; Parent F; Bros A; Fischer AM; Camez A; Simonneau G; Duroux P; Meyer D
Am J Hematol; 1995 May; 49(1):67-72. PubMed ID: 7741141
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study.
Parent F; Bridey F; Dreyfus M; Musset D; Grimon G; Duroux P; Meyer D; Simonneau G
Thromb Haemost; 1993 Sep; 70(3):386-8. PubMed ID: 8259534
[TBL] [Abstract][Full Text] [Related]
3. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
7. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
8. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
9. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy.
Saito M; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Aoshima K; Matsuda T
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):60-4. PubMed ID: 7540878
[TBL] [Abstract][Full Text] [Related]
10. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin.
Zoldhelyi P; Bichler J; Owen WG; Grill DE; Fuster V; Mruk JS; Chesebro JH
Circulation; 1994 Dec; 90(6):2671-8. PubMed ID: 7994807
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
Zhang B; Wieslander JB
Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
[TBL] [Abstract][Full Text] [Related]
12. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
13. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
15. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction.
Zeymer U; Mateblowski M; Neuhaus KL
Eur Heart J; 1996 Dec; 17(12):1836-40. PubMed ID: 8960425
[TBL] [Abstract][Full Text] [Related]
16. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-Hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma.
Gallistl S; Muntean W
Thromb Haemost; 1994 Sep; 72(3):387-92. PubMed ID: 7855789
[TBL] [Abstract][Full Text] [Related]
18. Clinico-pharmacological studies with recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J; Vogel G
Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
20. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
Kottke-Marchant K; Bahit MC; Granger CB; Zoldhelyi P; Ardissino D; Brooks L; Griffin JH; Potthoff RF; Van de Werf F; Califf RM; Topol EJ
Eur Heart J; 2002 Aug; 23(15):1202-12. PubMed ID: 12127922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
